[HTML][HTML] Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring …
A Hill, RP Rother, L Arnold, R Kelly, MJ Cullen… - …, 2010 - ncbi.nlm.nih.gov
A Hill, RP Rother, L Arnold, R Kelly, MJ Cullen, SJ Richards, P Hillmen
Haematologica, 2010•ncbi.nlm.nih.govBackground Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia
characterized by intravascular hemolysis which has been demonstrated to be effectively
controlled with eculizumab. However, lactate dehydrogenase levels remain slightly elevated
and haptoglobin levels remain low in some patients suggesting residual low-level
hemolysis. This may be due to C3-mediated clearance of paroxysmal nocturnal
hemoglobinuria red blood cells through the reticuloendothelial system.
characterized by intravascular hemolysis which has been demonstrated to be effectively
controlled with eculizumab. However, lactate dehydrogenase levels remain slightly elevated
and haptoglobin levels remain low in some patients suggesting residual low-level
hemolysis. This may be due to C3-mediated clearance of paroxysmal nocturnal
hemoglobinuria red blood cells through the reticuloendothelial system.
Abstract
Background
Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab. However, lactate dehydrogenase levels remain slightly elevated and haptoglobin levels remain low in some patients suggesting residual low-level hemolysis. This may be due to C3-mediated clearance of paroxysmal nocturnal hemoglobinuria red blood cells through the reticuloendothelial system.
ncbi.nlm.nih.gov
